98%
921
2 minutes
20
Purpose: To develop and evaluate the performance of a polygenic risk score (PRS) constructed in a Korean male population to predict clinically significant prostate cancer (csPCa).
Materials And Methods: Total 2,702 PCa samples and 7,485 controls were used to discover csPCa susceptible single nucleotide polymorphisms (SNPs). Males with biopsy-proven or post-radical prostatectomy Gleason score 7 or higher were included for analysis. After genotype imputation for quality control, logistic regression models were applied to test association and calculate effect size. Extracted candidate SNPs were further tested to compare predictive performance according to number of SNPs included in the PRS. The best-fit model was validated in an independent cohort of 311 cases and 822 controls.
Results: Of the 83 candidate SNPs with significant PCa association reported in previous literature, rs72725879 located in showed the highest significance for PCa risk (odds ratio, 0.597; 95% confidence interval [CI], 0.555-0.641; p=4.3×10). Thirty-two SNPs within 26 distinct loci were further selected for PRS construction. Best performance was found with the top 29 SNPs, with AUC found to be 0.700 (95% CI, 0.667-0.734). Males with very-high PRS (above the 95th percentile) had a 4.92-fold increased risk for csPCa.
Conclusions: Ethnic-specific PRS was developed and validated in Korean males to predict csPCa susceptibility using the largest csPCa sample size in Asia. PRS can be a potential biomarker to predict individual risk. Future multi-ethnic trials are required to further validate our results.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8756152 | PMC |
http://dx.doi.org/10.4111/icu.20210305 | DOI Listing |
Geroscience
September 2025
Department of Urology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
This study aims to investigate the predictive value of combined phenotypic age and phenotypic age acceleration (PhenoAgeAccel) for benign prostatic hyperplasia (BPH) and develop a machine learning-based risk prediction model to inform precision prevention and clinical management strategies. The study analyzed data from 784 male participants in the US National Health and Nutrition Examination Survey (NHANES, 2001-2008). Phenotypic age was derived from chronological age and nine serum biomarkers.
View Article and Find Full Text PDFEur Urol Focus
September 2025
Department of Urology, University Hospital Zürich, University of Zürich, Zürich, Switzerland.
Background And Objective: While whole-gland therapies for localized prostate cancer (PCa) offer excellent oncological outcomes, these can impact patients' quality of life (QoL) through serious side effects. Focal therapy using high-intensity focused ultrasound (HIFU) has emerged as a less invasive alternative to preserve QoL. However, data on the psychological impact of HIFU remain rare.
View Article and Find Full Text PDFNihon Hoshasen Gijutsu Gakkai Zasshi
September 2025
Department of Radiation Oncology, Koritsu Tatebayashi Kosei General Hospital.
Purpose: The promotion of task-shifting and task-sharing to facilitate work style reform for physicians has enabled radiological technologists (RTs) to perform primary matching in image-guided radiotherapy. The purpose in this study is to evaluate the position matching accuracy of RTs and radiation oncologist (ROs).
Methods: Position matching was performed by four RTs and two ROs (RO-A and B).
J Natl Compr Canc Netw
September 2025
1Harvard Medical School, Boston, MA.
Background: Previous studies have operationalized the NCCN list of high-risk medications in older adults into a measurable tool known as the Geriatric Oncology Potentially Inappropriate Medications (GO-PIMs) scale. The current study aims to evaluate the ability of GO-PIMs to identify high-risk medications and their impact on patients with both solid and liquid tumors managed in a large national health care system.
Methods: We performed a retrospective cohort study using data from the national Veterans Affairs (VA) Cancer Registry and electronic health records, including all veterans newly diagnosed with a solid or liquid malignancy from 2000 to 2022.
Cancer Treat Res Commun
September 2025
Maoming People's Hospital, China. Electronic address:
Prostate cancer represents the second most prevalent malignancy among males globally, exhibiting a significantly lower 5-year survival rate in China relative to Western nations. Early diagnosis constitutes a critical factor in enhancing clinical outcomes. Ultrasound molecular imaging has emerged as a non-invasive and widely accessible diagnostic modality.
View Article and Find Full Text PDF